

TGF-beta signaling in cartilage homeostasis and osteoarthritis

Kenneth W Finnson¹, Yoon Chi¹, George Bou-Gharios³ Andrew Leask², Anie Philip¹

¹*Division of Plastic Surgery, Department of Surgery, Montreal General Hospital, McGill University, Montreal, QC, H3G 1A4 Canada,* ²*Division of Oral Biology, Department of Dentistry, Schulich School of Medicine and Dentistry, University of Western Ontario, Dental Sciences Building, London ON N6A 5C1 Canada,* ³*Kennedy Institute of Rheumatology, Imperial College London, London, W6 8LH, UK*

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Overview of TGF- β signaling
 - 3.1. TGF- β family
 - 3.2. TGF- β synthesis and activation of latent TGF- β
 - 3.3. TGF- β receptors and signaling pathways
 - 3.4. Regulation of TGF- β signaling
 - 3.4.1. Extracellular control
 - 3.4.2. Intracellular control
4. TGF- β action in cartilage
5. Deregulation of TGF- β signaling in osteoarthritis
 - 5.1. TGF- β isoform expression
 - 5.2. TGF- β activation
 - 5.3. TGF- β receptor expression
 - 5.4. Smad2/3 signaling
 - 5.5. Smad1/5 signaling
 - 5.6. Smad7/Smurf2 activity
 - 5.7. Non-Smad pathways
 - 5.8. TGF- β co-receptors
6. TGF- β signaling pathway as a therapeutic target for osteoarthritis
7. Concluding remarks
8. References

1. ABSTRACT

Healthy cartilage is maintained by a delicate balance between the anabolic and catabolic activities of articular chondrocytes. This involves actions of numerous cytokines and growth factors that regulate the synthesis and degradation of extracellular matrix components which maintain the functional integrity of the joint. An imbalance between the activities of these anabolic and catabolic factors leads to cartilage degradation resulting in osteoarthritis (OA), a chronic degenerative joint disorder characterized by destruction of articular cartilage, alterations of subchondral bone and synovial fibrosis. Among the cytokines and growth factors that have been studied in the context of cartilage homeostasis and OA, transforming growth factor-beta- TGF-beta has emerged as an important molecule that plays a critical

role in the development, growth, maintenance and repair of articular cartilage. Deregulation of its signaling and responses has been shown to be involved in OA. Several components of the TGF-beta pathway, including extracellular, cell surface and intracellular molecules, display altered expression or action in OA. In this review, we discuss the regulatory mechanisms of TGF- beta signaling and link these mechanisms to cartilage function, highlighting the important role of TGF- beta in maintaining cartilage function and integrity. We also summarize the alterations in the molecular events of TGF- beta signaling and responses that may contribute to OA progression and discuss the potential of targeting the TGF-beta signaling pathway for the development of novel therapies for OA.

2. INTRODUCTION

Transforming growth factor- β (TGF- β) is a multifunctional growth factor that plays a critical role in cartilage development, homeostasis and repair (1-3). Impaired TGF- β signaling has been implicated in a variety of cartilage-related disorders including gout (4, 5), lupus (6-7), rheumatoid arthritis (8) and osteoarthritis (OA) (3, 9, 10). Although much progress in understanding the mechanism of TGF- β action in normal and OA cartilage has been made, this knowledge has not yet led to therapies that slow or reverse the progression of the disease. The purpose of this review is to highlight recent advances in understanding the role of TGF- β signaling in normal cartilage, the deregulation of TGF- β action in osteoarthritis (OA) and the potential of targeting TGF- β signaling pathway as a therapeutic strategy for the treatment of OA.

3. OVERVIEW OF TGF- β SIGNALING

3.1. TGF- β family

The TGF- β superfamily of growth factors, with more than 30 members including TGF- β s, activins and bone morphogenetic proteins (BMPs), are critical for metazoan development and homeostasis (11-13). They regulate diverse cellular processes including proliferation, differentiation, migration and apoptosis as well as extracellular matrix (ECM) production and degradation (11-14). Although the three mammalian TGF- β isoforms (TGF- β 1, - β 2, - β 3) share significant sequence (71-79% identity) and structural similarity (15-19), the non-overlapping phenotypes of TGF- β isoform-specific null mice suggest that they have unique functions *in vivo* (20). Moreover, TGF- β isoforms display distinct spatial and temporal expression in developing tissues, regenerating tissues and in pathologic responses (21).

3.2. TGF- β synthesis and activation of latent TGF- β

TGF- β is synthesized as a homo-dimeric pro-protein (pro-TGF- β). It is cleaved in the trans-Golgi network by furin-like enzymes resulting in the formation of the mature TGF- β dimer and the pro-peptide, also known as latency associated peptide (LAP). The LAP has a high affinity for the mature TGF- β and remains non-covalently associated with it, rendering it inactive. In most cases, this small latent complex is bound to latent TGF- β binding protein (LTBP) which forms a disulphide bond with the LAP, giving rise to the large latent complex, the most abundant secreted form. Once secreted, the large latent complex associates with the ECM by covalent cross-linking of LTBP with ECM proteins by transglutaminase (22-25).

Activation of latent TGF- β , which represents the liberation of TGF- β from its latent complex, is required for TGF- β binding to its receptors and to exert its biological effects (25). Latent TGF- β can be activated by physical processes such as acidification, alkalization and heat denaturation, as well as biological processes involving proteolysis or protein-protein interactions (22, 24-26). Many serine proteases including plasmin and thrombin, and

metalloproteinases such as MMP-2, -9, -13 and -14 have been implicated in TGF- β activation (24). In addition, the matricellular protein thrombospondin-1 (TSP-1) interacts with LAP directly and is thought to activate latent TGF- β by causing a conformational change in LAP that prevents it from conferring latency to TGF- β (27). Also, the integrins, α v β 6 and α v β 8 have been shown to contribute to activation of latent TGF- β via protease-dependent and protease-independent mechanisms (26, 28, 29). Although the precise context and mechanistic details of TGF- β activation by these unrelated groups of factors are ill-defined, the process of activation is seemingly controlled in a temporal, spatial and isoform-specific manner, and is likely to be a critical mechanism for regulating TGF- β bioavailability (22, 24-26).

3.3. TGF- β receptors and signaling pathways

Bioactive TGF- β signals through a pair of transmembrane serine/threonine kinases known as the TGF- β type II (T β RII) and type I (T β RI or activin receptor-like kinase-5; ALK5) receptors (11-13, 30). TGF- β binds T β RII, a constitutively active kinase, which then phosphorylates T β RI/ALK5 resulting in activation of ALK5 kinase activity (31, 32). Activated ALK5 then phosphorylates two receptor-regulated Smad (R-Smad) proteins, Smad2 and Smad3, which bind to the common mediator Smad (co-SMAD), Smad4, and translocate to the nucleus where they interact with various co-activators, co-repressors and transcription factors to regulate gene expression (33, 34). TGF- β has also been shown to activate another TGF- β type I receptor known as ALK1 which phosphorylates three different R-Smads i.e. Smad-1, -5 and -8 (35-37). In addition to Smad signaling, TGF- β also activates several non-Smad pathways including the MAPK kinase pathways (ERK, JNK and p38), Rho-like GTPase signaling pathways and phosphatidylinositol-3-kinase (PI3K)/AKT pathways (38-40).

3.4. Regulation of TGF- β signaling

The pleiotropic effects of TGF- β suggest that its signaling activity requires tight regulation. This is achieved through the action of many extracellular and intracellular proteins that co-ordinately control TGF- β action in a spatial, temporal and cell-type dependent manner.

3.4.1. Extracellular control

The control of TGF- β signaling at the extracellular level includes regulation of TGF- β synthesis and activation of latent TGF- β . Factors regulating TGF- β expression are poorly defined, although auto-induction and hypoxia are well documented (41-47). Activation of latent TGF- β , a process believed to be strictly regulated, is controlled by a variety of factors as discussed above (24-26). In addition to LAP and LTBP, molecules such as lipoproteins have been shown to sequester TGF- β ligand into an inactive pool (48). At the cell surface level, TGF- β co-receptors including endoglin, betaglycan (type III TGF- β receptor) and CD109 are emerging as important regulators of TGF- β signaling. These molecules are critical for normal development and adult tissue homeostasis and

their aberrant expression has been reported in many pathological conditions (49-52). Endoglin is a homodimeric single-pass transmembrane glycoprotein predominantly expressed on endothelial cells that binds TGF- β 1 and TGF- β 3 with high affinity in the presence of T β RII but does not bind the TGF- β 2 isoform (51). In endothelial cells, this co-receptor has been reported to (i) alter the phosphorylation status of T β RII and T β RI (ALK1 and ALK5), (ii) promote TGF- β /ALK1 signaling, (iii) inhibit TGF- β /ALK5/Smad2/3 signaling and (iv) antagonize TGF- β -induced MAP kinase signaling through a mechanism that involves interaction with β -arrestin-2 (53, 54). These findings suggest that endoglin's regulation of TGF- β signaling occurs at multiple levels involving complex mechanisms. Betaglycan, a homologue of endoglin, is a ubiquitously expressed transmembrane protein that binds all three TGF- β isoforms (TGF- β 1, - β 2, - β 3) with high affinity and enhances their binding to the signaling receptors (51, 55). Betaglycan has been shown to direct clathrin-mediated endocytosis of TGF- β types I and II receptors (56), and enhance TGF- β signaling via Smad and MAP kinase (57-59) pathways. On the other hand, betaglycan has also been reported to promote β -arrestin2-dependent TGF- β receptor internalization and down-regulation of TGF- β signaling (60). Further research is required to fully delineate the mechanisms involved in betaglycan's regulation of TGF- β signaling. CD109 is a GPI-anchored protein and member of the α 2-macroglobulin/complement family previously shown to be expressed on activated T-cells and platelets, endothelial cells and a variety of human cancer cell lines (61-64). We have recently identified CD109 as a TGF- β co-receptor and a component of the TGF- β receptor system (65). CD109 binds TGF- β 1 with high affinity and forms a heteromeric complex with the TGF- β signaling receptors, inhibiting Smad2/3 signaling in different cell types (65, 66). Our recent results indicate that CD109 inhibits TGF- β signaling by promoting TGF- β receptor internalization and degradation in a Smad7/Smurf2-dependent manner (66). Recent reports by others indicate that CD109 expression is upregulated in several cancers and that its expression is strictly regulated in normal tissues (50, 52, 62, 65, 67-70). Together, these studies demonstrate that endoglin, betaglycan and CD109 play critical roles in regulating TGF- β signaling in different cell types.

3.4.2. Intracellular control

Intracellularly, TGF- β signaling is regulated by a plethora of cytoplasmic proteins including FKBP12, TRIP-1, STRAP, TRAP-1, SARA, HSP90 (71) and nuclear proteins such as TGF β I, c-Ski, SnoN and Evi-1 (34) that control TGF- β signaling intensity, duration and termination. The inhibitory Smads or I-Smads, Smad6 and Smad7, play critical roles in negative feedback regulation of TGF- β /BMP signaling by forming stable complexes with the activated type I receptors thereby blocking R-Smad phosphorylation (72). In addition, Smad6 and Smad7 also act as adaptor proteins for E3 ubiquitin ligases such as Smurf1 and Smurf2 that induce ubiquitination and proteosomal degradation of the activated type I receptors

(73). Smad7 may also recruit protein phosphatase 1 α to ALK1 to reduce TGF- β /ALK1-induced Smad1/5 phosphorylation (74).

4. TGF- β ACTION IN CARTILAGE

Articular cartilage, an avascular tissue, receives its nutrients from the synovial fluid. Chondrocytes, the only cells found in cartilage, are embedded in an extensive extracellular matrix consisting mainly of collagens and proteoglycans (75). Type II collagen makes up about 85-90% of the collagen in articular cartilage and provides tensile strength to the tissue (76, 77). Aggrecan is the major proteoglycan of articular cartilage and provides structural support by retaining water in the matrix (78). Articular cartilage has a hierarchical structure that is divided into four distinct zones: 1) superficial zone, 2) middle zone, 3) deep zone and 4) calcified cartilage zone where the cartilage interfaces with the bone (75). The zones differ in collagen organization, proteoglycan content and chondrocyte morphologies (75).

TGF- β plays multiple roles in the development, growth and maintenance of articular cartilage. TGF- β stimulates early events in chondrogenesis including chondrogenic condensation via stimulation of fibronectin synthesis and N-CAM regulation (79, 80) and chondroprogenitor cell proliferation and differentiation via Smad3-dependent activation of SOX9 transcription (81, 82). It also inhibits terminal differentiation of chondrocytes to the hypertrophic phenotype thereby blocking cartilage matrix calcification, vascular invasion, osteoblastic differentiation and ossification (3, 9), leading to the formation of articular cartilage at the end of the long bones, through a Smad3-dependent mechanism (83).

The maintenance of articular cartilage is critically dependent on a balance between the anabolic and catabolic cytokines and growth factors that it elaborates. TGF- β -mediated anabolic signaling represents a crucial aspect of articular cartilage matrix turnover and homeostasis (1, 3). Not only does TGF- β stimulate the production of ECM proteins such as type II collagen and aggrecan, but it also blocks degradation of ECM proteins by increasing production of protease inhibitors such as TIMP (1, 3). Moreover, TGF- β can counteract the catabolic effects of IL-1 and TNF- α on cartilage degradation (1, 3).

In addition to growth factors, mechanical loading plays a major role in cartilage development and homeostasis (84). Mechanical forces stimulate the synthesis of ECM proteins and are important to maintain cartilage integrity. While excessive load can damage cartilage structure, some mechanical stimulation is necessary to promote chondrogenesis. Also, cartilage that is not mechanically stimulated is known to atrophy (85). An interesting concept in current cartilage research is that chondrocytes act as mechanosensors that alter their metabolism in response to local physico-chemical changes in the microenvironment (86). Such alterations may include changes in gene expression and production of matrix

degrading enzymes (86, 87). In this regard, several studies have reported an important role for TGF- β in mediating chondrocyte responses to mechanical forces. For example, shear forces were shown to increase chondrocyte proliferation (88) and stimulate expression of superficial zone protein (SZP) (89) in TGF- β -dependent manners. Accordingly, exogenous TGF- β alters the biomechanical properties of chondrocytes in terms of their 'stiffness' and 'compressibility' (90) and decreases the friction of articular cartilage (91). Moreover, TGF- β 3 and mechanical factors appear to act synergistically to enhance the functional properties of tissue-engineered articular cartilage (92-94). These studies emphasize the importance of considering mechanical factors in the context of TGF- β signaling and chondrocyte biology.

The potent effects of TGF- β on articular cartilage *in vivo* in animal models are well documented. Injection of TGF- β into the periosteum of rat or mouse femur induces chondrocyte differentiation and cartilage formation (95, 96). Local administration of TGF- β into murine knee joints stimulated articular cartilage repair (97) and healing of full thickness cartilage defects (98, 99). Also, inhibition of endogenous TGF- β during experimental OA impaired articular cartilage repair (100). In addition, expression of a dominant negative type II TGF- β receptor in cartilage resulted in OA-like phenotype in the mouse (101). Furthermore, Smad3 knockout mice develop degenerative joint disease resembling human arthritis (83) and Smad3 deficient chondrocytes exhibit enhanced BMP signaling and inappropriate terminal maturation (102). In addition, decreased TGF- β expression and Smad2 signaling are associated with loss of TGF- β protective effect during OA progression (103). Furthermore, evidence for a causal relationship between TGF- β and OA in the human is indicated by the recent identification of asporin (a proteoglycan that sequesters TGF- β in the ECM and inhibits TGF- β function) as an OA susceptibility gene (104-107). However, TGF- β also has been shown to have undesirable effects on cartilage. A number of studies have reported that TGF- β administration or overexpression in normal murine joints is associated with stimulation of osteophyte outgrowth, inflammation or synovial fibroplasia, although proteoglycan synthesis is enhanced (108-110). It is possible that normal cartilage function is dependent on a narrow range of bioactive TGF- β levels and concentrations below or above may lead to alterations in TGF- β signaling pathways and their integration, resulting in abnormal cartilage function.

5. DEREGULATION OF TGF- β SIGNALING IN OSTEOARTHRITIS

Osteoarthritis (OA) is a chronic degenerative joint disorder characterized by destruction of articular cartilage (111, 112). The etiology of OA is unknown but some of the common risk factors include aging, obesity, abnormal mechanical loading, genetics and anatomical abnormalities (113). Although cartilage degradation is a hallmark of OA, studies indicate that other components of the joint tissue, including subchondral bone and synovial

membrane, play a significant role in OA pathogenesis. Indeed, subchondral bone alterations may precede cartilage degradation and contribute to the initiation and/or progression of OA by producing catabolic factors that degrade the overlying cartilage (114). Synovial inflammation and synovitis occur in early and clinical stages of OA, respectively, and are thought to be induced by cartilage matrix degradation products that are phagocytosed by synovial lining macrophages which, in turn, secrete pro-inflammatory mediators into the synovial fluid that diffuse into the cartilage, thereby creating a vicious circle of synovial inflammation and cartilage degradation (114). In addition, although moderate mechanical loading maintains the integrity of articular cartilage, both disuse and overuse can contribute to cartilage degradation (115). Thus, abnormal biochemical or biomechanical activity in cartilage, subchondral bone and synovial membrane likely contributes to the imbalance between anabolic and catabolic factors in cartilage, leading to cartilage degradation and OA (1, 3). A detailed analysis of the contributions of abnormal mechanical loading and subchondral bone alterations to the pathogenesis of OA are beyond the scope of this review and the reader is referred to some excellent recent reviews (87, 112, 114-117). The current review is centered on the role of aberrant TGF- β signaling in articular cartilage homeostasis and OA. Available information pertaining to alterations in the components of the TGF- β signalling pathway in human OA and animal models of OA and the potential of targeting the TGF- β pathway for therapeutic intervention in OA is reviewed below and summarized in Tables 1-3.

5.1. TGF- β isoform expression

Several studies suggest that expression levels of the TGF- β isoforms (TGF- β 1, - β 2, - β 3) are down-regulated in OA. These include reports showing that TGF- β 1 protein levels are decreased in human OA cartilage as compared to normal cartilage (118, 119), that TGF- β 1 and TGF- β 2 mRNA levels are slightly decreased in OA cartilage in a rabbit model (120), and that TGF- β 3 levels are reduced in cartilage during OA progression in both spontaneous (STR/Ort) and collagenase-induced mouse models of OA (103). However, several other studies have reported opposite results. For example, TGF- β 1, - β 2 and - β 3 levels have been shown to be increased in human OA (121-123). In addition, TGF- β 1 and - β 3 levels were elevated in a papain-induced mouse model of OA (100) whereas TGF- β 2 was increased in a surgically-induced model of early OA in rats (124). One possible explanation for the discrepancy in these results is that TGF- β isoform expression in OA may vary during the course of the disease, and may depend on factors such as age, gender, genetics and mechanical factors (obesity, trauma). It is possible that TGF- β isoform expression increases in the early stages of OA in an attempt to counteract the catabolic effects of inflammatory cytokines such as IL-1 β or TNF- α (10, 125) or as an adaptive response to the progressive loss of TGF- β receptor expression but then decreasing due to loss of TGF- β auto-induction (46). While such alterations in TGF- β isoform expression at the transcriptional level undoubtedly play a role in the deregulation of TGF- β

Table 1. TGF- β signaling components that are altered in osteoarthritis

Component	Model	Alteration	Reference
TGF- β 1	Human OA	↓TGF- β 1 protein (proteomics)	118
	Human OA	↓TGF- β 1 protein (IHC)	119
	Human OA	↑TGF- β 1 mRNA (qPCR) and protein (IHC)	122
	Human OA	↑TGF- β 1 mRNA (microarray and qPCR)	123
	Mouse OA (papain)	↑TGF- β 1 protein (IHC and ELISA)	100
	Rabbit ACLT/PCLT	↓TGF- β 1 mRNA (RT-PCR)	120
TGF- β 2	Human OA	↑TGF- β 2 protein (proteomics)	121
	Human OA	↑TGF- β 2 mRNA (qPCR) and protein (IHC)	122
	Rat OA (ACLT)	↑TGF- β 2 mRNA (microarray)*	124
	Rabbit ACLT/PCLT	↓TGF- β 2 mRNA (RT-PCR)	120
	Mouse Aging	↓TGF- β 2 protein (IHC)	145
TGF- β 3	Human OA	↑TGF- β 3 mRNA (qPCR) and protein (IHC)	122
	Human OA	↑TGF- β 3 mRNA (microarray)**	123
	Mouse OA (papain)	↑TGF- β 3 protein (IHC and ELISA)	100
	Mouse OA (STR/Ort)	↓TGF- β 3 protein (IHC)	103
	Mouse OA (CIA)	↓TGF- β 3 protein (IHC)	103
	Mouse Aging	↓TGF- β 3 protein (IHC)	145
LTBP-1	Human OA	↑LTBP-1 mRNA (microarray)*	136
	Rat OA (ACLT)	↑LTBP-1 mRNA (microarray)*	124
LTBP-2	Human OA	↑LTBP-2 mRNA (microarray)*	136
	Human OA	↑LTBP-2 mRNA (microarray)*	127
	Rat OA (ACLT)	↑LTBP-2 mRNA (microarray)*	124
	Rat OA (MT)	↑LTBP-2 mRNA (microarray)*	126
TG-2	Human OA	↑TG-2 protein (IHC)	130
	Human OA	↑TG-2 activity (IHC of cross-linked cartilage)	131
	Human OA	↑TG-2 protein (IHC)	132
	Mouse OA (MLT)	↑TG-2 protein (IHC)	132
TSP-1	Human OA	↑TSP-1 protein in mild or moderate OA and ↓TSP-1 protein in severe OA (IHC)	134
F-Spondin	Human OA	↑F-spondin mRNA (qPCR) and protein (WB and IHC)	135
	Human OA	↑F-spondin mRNA (microarray)*	136
	Rat OA (ACLT + PM)	↑F-spondin mRNA (microarray)* and protein (IHC)	135
T β RII	Human OA	↓T β RII protein (IHC)	119
	Mouse Aging	↓T β RII protein (IHC)	145
	Rabbit OA	↓T β RII protein (RT-PCR)	120
ALK5	Human OA	ALK5 mRNA correlates with COL2 + AGG mRNA expression (qPCR)	143
	Mouse Aging	↓ALK5 protein (IHC)	143
	Mouse OA (STR/Ort)	↓ALK5 protein (IHC)	143
	Mouse OA (DMM)	↓ALK5 protein (IHC)	143
	Rat OA (PM/PST)	↓ALK5 protein (IHC)	144
ALK1	Human OA	ALK1 mRNA correlates with MMP-13 mRNA expression (qPCR)	143
	Mouse OA (STR/Ort)	↓ALK1 protein (IHC); ↑ALK1/ALK5 ratio	143
	Mouse OA (DMM)	↓ALK1 protein (IHC); ↑ALK1/ALK5 ratio	143
	Mouse Aging	↓ALK1 protein (IHC); ↑ALK1/ALK5 ratio	143
	Rat OA (MT)	↑ALK1 protein (IHC); ↑ALK1/ALK5 ratio	126
Smad2	Mouse OA (STR/Ort)	↓phospho-Smad2 (IHC)	103
	Mouse OA (CIA)	↓phospho-Smad2 (IHC)	103
	Mouse aging	↓phospho-Smad2 (IHC)	145
Smad3	Human OA	Smad3 missense mutation a risk factor for OA	148
	Human OA	Smad3 intronic SNP a risk factor for OA	149
	Mouse aging	↑Smad3 protein (IHC)	145
Smad7	Mouse aging	↑Smad7 protein (IHC)	145
Smurf2	Human OA	↑Smurf2 protein (IHC)	160
Eg	Human OA	↑Eg protein (WB and IHC)	167
	Human OA	↑soluble Eg in plasma and synovial fluid correlates with OA progression	168
	Human OA	↑endoglin mRNA (microarray)*	127
	Rat OA (ACLT)	↑endoglin mRNA (microarray)	124

IHC, immunohistochemistry; MLT, multiple ligament transection; ACLT, anterior cruciate ligament transection; PCLT, posterior cruciate ligament transection; MT, meniscal tear; PM, partial meniscectomy; DMM, destabilization of the medial meniscus; CIA, collagenase-induced arthritis; PM/PST, partial meniscectomy/post-surgical training; WB, Western blot; SNP, single nucleotide polymorphism; Eg, endoglin. COL2, type II collagen; AGG, aggrecan; *not validated by qPCR. **not replicated by qPCR.

Table 2. Mouse models with altered TGF- β signaling components that display OA characteristics

Component	Model	Findings	References
LTBP-3	Mouse LTBP-3 KO	OA phenotype	128
TG-2	Mouse TG-2 KO	↓cartilage destruction and ↑osteophyte formation in transgenic mice as compared to WT mice	132
T β RII	Mouse DN T β RII transgenic	OA phenotype	101
Smad3	Mouse Smad3 KO	OA phenotype	83
	Mouse Smad3 KO	cartilage degradation	147
Smurf2	Mouse Smurf2 transgenic	OA phenotype	160

KO, knockout; WT, wild-type; DN, dominant-negative.

Table 3. Therapeutic effects of targeting the TGF- β pathway in experimental OA

Therapy	Model	Findings	Refs
Ad TSP-1	Rat CIA	↓severity of CIA	137
Ad TSP-1	Rat ACLT	↓OA progression	138
TGF- β 1 protein	Rabbit OA TMJ	↓cartilage damage	179
TGF- β 1 protein	Mouse IL-1-induced cartilage damage	↓cartilage damage	180
TGF- β 1 protein	Normal mouse	↑PG synthesis and content, ↑inflammation, synovial hyperplasia and osteophyte formation	108
TGF- β 1 protein	Normal mouse	↑PG synthesis/content and ↑osteophyte formation	109
Ad TGF- β 1 ^{223/225}	Normal mouse	↑PG synthesis and content, ↑inflammation, synovial hyperplasia and osteophyte formation	110
Ad TGF- β 1 ^{223/225}	Mouse IL-1-induced cartilage damage	TGF- β 1 restored IL-1-induced ↓ in PG synthesis/content	183
AdLAP	Mouse OA (papain)	↓osteophyte formation; ↓PG	182
AdSmad7	Mouse OA (papain)	↓osteophyte formation; ↓synovial thickening	182
AdSmad7	Mouse IL-1-induced cartilage damage	↓TGF- β 1-induced synovial fibrosis	183

CIA, collagenase-induced arthritis; Ad, adenovirus; ACLT, anterior cruciate ligament transection; TMJ, temporomandibular joint; PG, proteoglycan; TGF- β 1^{223/225}, active TGF- β 1

action in OA, any changes in the activation of the secreted TGF- β can be of critical importance since TGF- β activation from its latent complexes controls TGF- β bioavailability.

5.2. TGF- β Activation

Several studies indicate that factors involved in latent TGF- β activation display altered expression in OA. Current data suggest that members of the LTBP family are differentially expressed in OA, which may lead to a decrease in TGF- β bioavailability. The expression of both LTBP-1 and LTBP-2 are upregulated in human OA cartilage (124, 126, 127) and in experimental models of OA (124, 126). In contrast, LTBP-3 knockout mice develop OA and display phenotypic changes that are similar to those of mice with impaired TGF- β signaling (128, 129). These observations demonstrating that increased LTBP-1/2 expression in humans and decreased LTBP-3 expression in mice are associated with OA are intriguing. Species-specific differences in the function of LTBP isoforms and/or their different TGF- β isoform-specificities may account for the seemingly discrepant findings (25). Interestingly, the levels of other molecules involved in the activation of latent TGF- β are also upregulated in human OA and in a variety of animal models of OA. Transglutaminase-2 (TG-2), the predominant transglutaminase subtype in hypertrophic chondrocytes are higher in knee (130, 131) and femoral (132) cartilage in human OA and in experimental OA models (124, 126, 133). Whether the enhanced TG-2 expression in OA correlates with increased TGF- β activation or LTBP cross-linking to ECM remains to be determined.

Similarly, TSP-1 levels are increased in the cartilage in mild and moderate OA, but decreased in severe OA (134). F-Spondin (Spondin-1), another member of the TSP-1 family known to activate latent TGF- β , is also elevated in human OA cartilage as compared to normal cartilage (135, 136) and in rat knee cartilage following surgical meniscectomy (135). Intra-articular gene transfer of TSP-1 was shown to reduce disease progression in a collagen- or anterior cruciate ligament transection (ACLT)-induced OA in rats (137, 138). This is consistent with the notion that TSP-1 mediates latent TGF- β activation in OA

cartilage and that the up-regulation of TSP-1 is an adaptive response in an attempt to increase cartilage repair. In addition, ascorbic acid, which plays a role in redox-mediated activation of latent TGF- β (139), was shown to increase collagen content as well as osteophyte formation, at least in part by TGF- β activation in a guinea pig OA model (140). Also, a recent report suggests that alendronate, a potent inhibitor of bone resorption, decreases osteophyte formation in the cartilage in a rat anterior cruciate ligament transection OA model, possibly by reducing activation of TGF- β via inhibition of MMP-13 expression (141).

5.3. TGF- β receptor expression

Increasing evidence indicates that TGF- β receptor expression levels are altered in OA. T β RII levels were shown to be decreased in human OA cartilage as compared to normal cartilage (119). In addition, T β RII mRNA levels in cartilage were also shown to be dramatically reduced at mid and late stages of OA in a rabbit model (120). Moreover, T β RII mRNA expression was decreased in cultured chondrocytes from OA donors as compared to chondrocytes from normal donors (142). These studies suggest that the loss of T β RII expression may contribute to the initiation and/or progression of OA. This notion is supported by the finding that a truncated, kinase-defective T β RII expressed in mouse skeletal tissue was associated terminal chondrocyte differentiation and the development of OA-like features (101). Thus, deregulation of T β RII expression levels likely represents a central component in the pathogenesis of OA.

Emerging evidence indicates that the expression of TGF- β type I receptors is also altered in OA. We have recently shown that, in addition to the canonical TGF- β type I receptor ALK5, human chondrocytes also express ALK1 and that both ALK5 and ALK1 are needed for TGF- β -induced Smad1/5 phosphorylation whereas only ALK5 is essential for TGF- β -induced Smad3 phosphorylation (37). In addition, ALK1 inhibits whereas ALK5 potentiates the expression of type II collagen and PAI-1 in chondrocytes, indicating that ALK1 and ALK5 have opposing functions in chondrocytes (37), as shown previously in endothelial cells (35, 36). More recent data suggest that although both

ALK5 and ALK1 expression are decreased in mouse models of OA, ALK1 expression decreases to a lesser extent than that of ALK5 , suggesting that the ratio of $\text{ALK1}/\text{ALK5}$ increases during OA (143). Also, ALK1 mRNA expression highly correlates with MMP-13 mRNA levels whereas ALK5 mRNA levels correlated with aggrecan and collagen type II levels in human OA cartilage (143). In addition, ALK1 has been identified as one of the genes upregulated in a meniscal tear rat model of OA (126) whereas ALK5 levels were dramatically reduced in partial meniscectomy and post-surgery training rat model of OA (144). Together these data suggest that alterations in the expression of TGF- β signaling receptors ($\text{T}\beta\text{RII}$ and $\text{ALK5}/\text{ALK1}$) play an important role in OA pathogenesis and that an increase in the TGF- β / ALK1 pathway activation relative to that of the TGF- β / ALK5 pathway activation is likely to be a critical event in OA disease progression.

5.4. Smad2/3 signaling

Since the expression levels of TGF- β signaling receptors are altered in OA, changes in the activity of their signal mediators Smad2/3 in OA can be anticipated. It has been shown that Smad2 phosphorylation levels are reduced in cartilage during OA progression in both spontaneous-(STR/Ort) and collagenase-induced mouse models of OA (103). Also, Smad2 phosphorylation is decreased in cartilage in old mice compared to young mice (145). Although Smad3 phosphorylation was not examined in these models, a recent study has reported decreased Smad3 phosphorylation levels in the Smurf-2 transgenic mice that spontaneously develop an OA-like phenotype (146). Together, these studies suggest that OA is associated with reduced TGF- β / $\text{ALK5}/\text{Smad2/3}$ signaling.

The potential importance of Smad3 in OA is underscored by the finding that Smad3 knockout mice develop a degenerative joint disease resembling human OA (83) and intervertebral disc degeneration (147). Furthermore, genetic studies showing that mutations in the human Smad3 gene may be a risk factor for susceptibility to OA. Accordingly, a missense mutation in the Smad3 gene is associated with elevated serum MMP-2 and MMP-9 levels in a patient with knee OA, suggesting that mutations in the Smad3 gene may be involved in the pathogenesis of human OA (148). A recent report indicates that a single nucleotide polymorphism mapping to Smad3 intron 1 is involved in risk of both hip and knee OA in European populations (149). The effects of the missense mutation and SNP on Smad3 function remain to be determined. However, collectively these findings indicate that a decrease or loss of Smad3 signaling likely plays an important role in the pathogenesis of OA. Delineating the mechanisms involved in the deregulation of $\text{ALK5}/\text{Smad3}$ signaling in OA is critical for understanding the role of TGF- β in the development of OA.

5.5. Smad1/5 signaling

The hypothesis that a shift in the balance of Smad1/5 versus Smad2/3 signaling plays an important role in OA pathogenesis has recently gained attention. TGF- β signals through both these pathways in human

chondrocytes with the Smad1/5 pathway opposing the Smad2/3 pathway (37). This is consistent with the findings in endothelial cells (35, 36), skin fibroblasts (150) and in chondrocyte terminal differentiation (151). The expression levels and subcellular localization *in vivo* of Smad-1, -5, and -8 in human OA were not significantly different from that of normal articular chondrocytes, although two Smad1 gene splice variants are reduced in OA cartilage (152). However, when the reported decrease in ALK5 expression and Smad2/3 signaling (see above) in OA cartilage is taken into account, a shift in the balance of Smad1/5 versus Smad2/3 signaling may occur, contributing to OA progression (9, 143). Factors that regulate the balance of signaling between these two TGF- β signaling pathways are not known. Although chondrocytes from mice null for Sulf-1 (an extracellular sulfatase up-regulated in OA cartilage) show reduced Smad1 protein expression and Smad1/5 phosphorylation (153, 154), it is not known whether this is accompanied by parallel changes in Smad2/3 signaling or whether Sulf-1 expression in human OA cartilage correlates with changes in the activation state of the $\text{ALK5}/\text{Smad2/3}$ and $\text{ALK1}/\text{Smad1/5}$ pathways. Identification of factors regulating the $\text{ALK5}/\text{Smad2/3}$ versus $\text{ALK1}/\text{Smad1/5}$ pathway may lead to the development of strategies to increase $\text{ALK5}/\text{Smad2/3}$ signaling while reducing $\text{ALK1}/\text{Smad1/5}$ signaling.

5.6. Smad7/Smurf2 activity

As alluded to earlier, Smad7/Smurf2 mediated TGF- β receptor degradation is an important mechanism for the termination of TGF- β signaling (72, 73). The potential role of Smad7 and Smurf2 in the development of OA is beginning to be elucidated. Although no difference in Smad7 expression is detected between normal and OA cartilage in the human (155), inflammatory cytokines such as IL-1 β increase Smad7 expression in human chondrocytes, leading to inhibition of TGF- β activity (156-158). Furthermore, murine cartilage displays an age-related increase in Smad7 expression (145), suggesting that Smad7 might be important in the initiation or progression of primary OA where aging is considered an important factor (9, 159). In addition, Smurf2 is increased in human OA cartilage as compared to normal cartilage (160) and Smurf2-transgenic mice spontaneously develop an OA-like phenotype that correlates with decreased TGF- β signaling and increased pSmad3 degradation (160).

5.7. Non-Smad pathways

Although the Smad pathway is central in mediating most TGF- β responses, TGF- β also activates non-Smad pathways including MAPK kinase (ERK, p38, JNK) pathways, Rho-like GTPase signaling pathways and PI3K/Akt pathways (38-40). However, the significance of the non-Smad pathways in mediating TGF- β responses in chondrocytes is largely unknown, despite the fact that such pathways have been shown to play important roles in regulating chondrocyte function (161). TGF- β -activated kinase-1 (TAK1), a MAP3 kinase activated by TGF- β , BMP and other MAP kinase signaling components, is a necessary mediator of cartilage development and function (162). It has been shown to mimic and mediate TGF- β -

induced stimulation of type II collagen synthesis in chondrocytes by translational/post-translational mechanisms in a Smad3-independent manner (163). Importantly, extensive cross-talk between the non-Smad and Smad pathways in chondrocytes has been demonstrated. Activation of MAPK kinase activity by cytokines such as interleukin-1 β or tumor necrosis factor- α decreases Smad3/4 DNA binding and ECM production in chondrocytes (158). In addition, ATF-2 works synergistically with Smad3 to mediate the inhibitory effect of TGF- β on chondrocyte maturation (164). Moreover, inhibition of PI3K, Akt, or mTOR blocks the ability of TGF- β to stimulate expression of the tissue inhibitor of metalloproteinase-3, an enzyme which is involved in the breakdown of ECM in normal physiological processes (161). Together, these studies demonstrate that TGF- β induced non-Smad signaling and the extensive cross-talk between the multiple signaling pathways play a critical role in maintaining cartilage function and integrity. Further research towards determining how the numerous pathways that are activated in chondrocytes in response to TGF- β are integrated to control chondrocyte behaviour is important to develop approaches to re-establish the balance of signaling that is disrupted in OA.

5.8. TGF- β co-receptors

TGF- β co-receptors such as endoglin, betaglycan and CD109 have emerged as important regulators of TGF- β signaling and responses with critical roles in diseases such as cancer and organ fibrosis (49-51, 55, 62, 65, 165). Available evidence suggests that these co-receptors may regulate TGF- β action in chondrocytes and that alteration in their expression and activities may contribute to OA progression.

5.8.1. Endoglin: We have previously shown that endoglin is expressed in human articular cartilage *in vivo* and in primary human articular chondrocytes *in vitro* (166). More recently, we demonstrated that endoglin regulates TGF- β signaling in chondrocytes, enhancing TGF- β -induced Smad1/5 signaling and inhibiting Smad2/3 signaling and ECM production in human chondrocytes (167). Furthermore, our results show that endoglin protein levels are increased in human OA chondrocytes as compared to normal chondrocytes *in vivo* (167). This is in agreement with a large-scale gene expression study suggesting that endoglin mRNA expression is increased in OA cartilage as compared to normal cartilage in humans (127), and in a surgically induced model of early OA in rats [(Data from Gene Expression Omnibus (GEO), DataSet Record GDS2809, Reference Series: GSE8077] (124). In addition, soluble endoglin in plasma and synovial fluid correlates with progressive joint damage in knee OA, suggesting that endoglin may be a useful biomarker for determining disease severity and/or play a role in the pathogenesis of OA (168).

5.8.2. Betaglycan: Expression and function of betaglycan in cartilage are only beginning to be explored. We have previously shown that betaglycan is expressed in human chondrocytes and that it forms a complex not only

with the signaling receptors but also with endoglin in a ligand- and T β RII-independent manner (166). A recent study has shown that betaglycan expression levels were similar in paired intact and damaged human OA cartilage (169) and did not change in a rat model of experimental OA (124). However, betaglycan expression was shown to be increased in response to mechanical injury to adult human articular cartilage (170) suggesting that deregulated betaglycan expression might play a role in secondary OA when joint trauma is involved. Interestingly, betaglycan expression was shown to be increased in mesenchymal stem cells (MSC) from the femur channel (171) and in trabecular bone from the iliac crest (172) of OA patients as compared to normal controls, suggesting that deregulated expression of betaglycan in non-cartilagenous tissues might play a role in OA pathogenesis.

5.8.3. CD109: This novel TGF- β co-receptor is an important regulator of TGF- β signaling, inhibiting Smad2/3 phosphorylation and enhancing TGF- β receptor degradation in other cell types (65, 173). There is limited information on the expression and function of CD109 in the cartilage. CD109 is present in the conditioned media of human articular chondrocytes in monolayer (174) and of bovine cartilage explants treated with interleukin-1 β or TNF- α (175). Our group has detected CD109 in OA and normal chondrocytes in monolayer culture and in their conditioned media (Finsson and Philip, unpublished data). Recently, CD109 was detected in peripheral circulation and synovial fluid as a component of CD146-positive lymphocytes (176).

As discussed above, TGF- β activates multiple signaling pathways. It is now well documented that activation of these different pathways occurs in a context and cell-type specific manner (11-13, 177, 178). All three of the TGF- β co-receptors mentioned above have the ability to bind TGF- β and associate with the TGF- β signaling receptors to form hetero-oligomeric complexes (probably of different subtype composition) on the cell surface and modulate signaling receptor activity (51, 65). Such regulation by the co-receptors may contribute to the activation of distinct TGF- β signaling pathways in different cell types, resulting in diverse responses of TGF- β .

6. TGF- β SIGNALING PATHWAY AS A THERAPEUTIC TARGET FOR OSTEOARTHRITIS

That several components of the TGF- β signaling pathway display altered expression in human OA cartilage and that genetic manipulation of these components in animal models leads to OA-like phenotypes suggests that the TGF- β pathway represents a suitable molecular target for therapeutic treatment of this disease. A number of studies have focused on the direct use of TGF- β as a therapeutic agent. Injection of TGF- β into the osteoarthritic temporomandibular joint of rabbits was shown to have a protective effect on articular cartilage degradation (179). In addition, TGF- β injection into IL-1 injected murine knee joints was shown to confer a protective effect against IL-1-induced articular cartilage damage (180, 181). Although




Figure 1. Schematic diagram showing the main components of the TGF- β /Smad signaling pathway as described in this review. TGF- β is secreted (1) in a latent form. It is activated (2) from its latent form by protease-dependent and protease-independent mechanisms such as protein-protein interactions. Active TGF- β signals through cell surface heteromeric receptor complexes containing type II (T β RII, green) and type I [ALK5 (blue) or ALK1 (red)] receptors. In normal chondrocytes, TGF- β signals predominantly via ALK5 (3A), which phosphorylates Smad2 and Smad3 proteins that form a complex with Smad4 and translocate to the nucleus to regulate expression of target genes including type II collagen and aggrecan. During OA, TGF- β may preferentially signal via ALK1 (3B) which phosphorylates Smad1 and Smad5 leading to increased MMP-13 expression and reduced type II collagen and aggrecan expression. Alterations in the expression of ALK5, ALK1 and endoglin in osteoarthritis may favour the shift in TGF- β signaling away from the ALK5-Smad2/3 pathway and towards ALK1-Smad1/5 signaling.

repeated injections of TGF- β 1 into a normal joint leads to prolonged elevation of proteoglycan synthesis and content in articular cartilage, it also induces inflammation, synovial hyperplasia and osteophyte formation (108-110). These studies indicate that although TGF- β has a beneficial effect on cartilage repair, it also has undesirable side effects. Recent reports suggest that adjuvant therapies can be used to circumvent the undesirable effects of TGF- β on cartilage repair. Thus, adenoviral delivery of Smad7 or LAP during experimental OA leads to a reduction in osteophyte formation and synovial thickening, while increasing the loss of proteoglycan in the articular cartilage, by inhibiting endogenous TGF- β action (182). Furthermore, adenoviral overexpression of TGF- β stimulates repair of IL-1- and OA-damaged cartilage and the TGF- β -induced synovial fibrosis is blocked by locally inhibiting TGF- β signaling in the synovial lining by simultaneous overexpression of Smad7 (183). These findings indicate that strategies that take advantage of the beneficial effects of TGF- β and block its adverse side effects will be a fruitful avenue for development of this molecule for OA therapy.

Strategies targeting factors that regulate latent TGF- β activation have also shown promise in pre-clinical studies. For example, intra-articular gene transfer of TSP-1 was shown to reduce disease progression in two different rat models of experimental OA (137, 138). TG inhibitors were shown to suppress calcium pyrophosphate dihydrate (CPPD) crystal formation by porcine chondrocytes (131) suggesting that this approach may be of benefit for the treatment of OA.

An alternative approach will be to target other components of the TGF- β signaling pathway in OA chondrocytes. For example, modulating the balance of signaling via ALK1 versus ALK5 might improve the cartilage repair effects of TGF- β . We have shown that ALK1 opposes ALK5/Smad2/3 signaling and collagen type II production in human chondrocytes (37), suggesting that ALK1 would interfere with the chondroprotective effects of TGF- β . Furthermore, others have shown that signaling via ALK1 but not ALK5 stimulates MMP13 expression, a hallmark of OA, in chondrocytes and that ALK5 expression correlates with type II collagen and aggrecan production whereas ALK1 expression correlates with MMP-13 expression in human OA cartilage (143). Thus, a better use of TGF- β for OA treatment will be to include strategies that simultaneously block ALK1 activity in chondrocytes. Such approaches include delivery of ALK1-specific shRNA driven by a type II collagen. Alternatively, molecules that modulate the balance of signaling via ALK1 versus ALK5 in OA chondrocytes can be targeted. We have shown that endoglin inhibits TGF- β /ALK5/Smad2/3 signaling and ECM production and promotes TGF- β /ALK1/Smad1/5 signaling in human chondrocytes (167) suggesting that abrogating endoglin expression in OA chondrocyte would have therapeutic benefit.

The use of co-receptors to regulate specific TGF- β signaling pathways to control chondrocyte gene expression that favour repair and inhibit undesirable effects is an attractive concept. Recent evidence shows that TGF- β co-receptors can act as dual modulators of TGF- β signaling and responses (51). In addition to their membrane anchored forms, the three TGF- β receptors also exist in soluble forms due to enzymatic shedding of their ectodomain and these soluble forms have been shown to bind and sequester TGF- β (65, 184-186). Thus administration of these proteins locally to the synovial lining may inhibit TGF- β 's undesirable side effects such as synovial fibroplasia as has been shown for Smad7-mediated inhibition of this process.

7. CONCLUDING REMARKS

TGF- β is an important growth factor in the development, maintenance and repair of articular cartilage. Studies to date indicate that several components of the TGF- β pathway including extracellular, cell surface and intracellular molecules display altered expression or activity in OA suggesting that they might represent potential targets for the development of novel therapeutic agents for the treatment of this disease. A schematic diagram showing the various sites for potential therapeutic intervention is depicted in Figure 1.

TGF- β has been shown to have a chondroprotective effect and its therapeutic utility might be improved by blocking its unwanted side effects by local inhibition of TGF- β activity in synovial tissues in an attempt to halt or reverse synovial fibrosis and osteophyte formation. TGF- β co-receptors such as endoglin, betaglycan and CD109, whose functional significance is only beginning to be explored in OA, have been shown to act as dual modulators of TGF- β action in cancer and other diseases (51). Application of these concepts to regulate TGF- β action in the cartilage may present exciting new possibilities to manipulate TGF- β signaling and action for the treatment of OA. Moreover, recent advances such as the discovery of a growing list of factors altered in OA including neogenin (187), Sulf-1 (154) and HIF-2 α (188-191) with potential to regulate specific TGF- β signaling pathways (153, 188-193) provide new research avenues for the development of novel therapies for OA.

8. REFERENCES

1. E. Blaney Davidson, P. van der Kraan and W. van den Berg: TGF- β and osteoarthritis. *Osteoarthritis Cartilage*, 15(6), 597-604 (2007)
2. B. Song, K. D. Estrada and K. M. Lyons: Smad signaling in skeletal development and regeneration. *Cytokine Growth Factor Rev*, 20(5-6), 379-88 (2009)
3. P. M. van der Kraan, E. N. Blaney Davidson, A. Blom and W. B. van den Berg: TGF- β signaling in chondrocyte terminal differentiation and osteoarthritis: modulation and integration of signaling pathways through receptor-Smads. *Osteoarthritis Cartilage*, 17(12), 1539-45 (2009)
4. S. J. Chang, C. J. Chen, F. C. Tsai, H. M. Lai, P. C. Tsai, M. H. Tsai and Y. C. Ko: Associations between gout tophus and polymorphisms 869T/C and -509C/T in transforming growth factor β 1 gene. *Rheumatology (Oxford)*, 47(5), 617-21 (2008)
5. N. Dalbeth, B. Pool, G. D. Gamble, T. Smith, K. E. Callon, F. M. McQueen and J. Cornish: Cellular characterization of the gouty tophus: a quantitative analysis. *Arthritis Rheum*, 62(5), 1549-56 (2010)
6. M. A. Kriegel, M. O. Li, S. Sanjabi, Y. Y. Wan and R. A. Flavell: Transforming growth factor- β : recent advances on its role in immune tolerance. *Curr Rheumatol Rep*, 8(2), 138-44 (2006)
7. E. Y. Kim and K. D. Moudgil: Regulation of autoimmune inflammation by pro-inflammatory cytokines. *Immunol Lett*, 120(1-2), 1-5 (2008)
8. D. Pohlers, J. Brenmoehl, I. Löffler, C. K. Müller, C. Leipner, S. Schultze-Mosgau, A. Stallmach, R. W. Kinne and G. Wolf: TGF- β and fibrosis in different organs - molecular pathway imprints. *Biochim Biophys Acta*, 1792(8), 746-56 (2009)
9. P. M. van der Kraan, E. N. Blaney Davidson and W. B. van den Berg: A role for age-related changes in TGF- β signaling in aberrant chondrocyte differentiation and osteoarthritis. *Arthritis Res Ther*, 12(1), 201 (2010)
10. C. J. Malemud: Anticytokine therapy for osteoarthritis: evidence to date. *Drugs Aging*, 27(2), 95-115 (2010)
11. M. Y. Wu and C. S. Hill: TGF- β superfamily signaling in embryonic development and homeostasis. *Dev Cell*, 16(3), 329-43 (2009)
12. K. Wharton and R. Derynck: TGF- β family signaling: novel insights in development and disease. *Development*, 136(22), 3691-7 (2009)
13. A. Moustakas and C. H. Heldin: The regulation of TGF β signal transduction. *Development*, 136(22), 3699-714 (2009)
14. C. Heldin, M. Landstrom and A. Moustakas: Mechanism of TGF- β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. *Current Opinion in Cell Biology*, 21(2), 166-176 (2009)
15. M. P. Schlunegger and M. G. Grütter: An unusual feature revealed by the crystal structure at 2.2 Å resolution of human transforming growth factor- β 2. *Nature*, 358(6385), 430-4 (1992)
16. P. R. Mittl, J. P. Priestle, D. A. Cox, G. McMaster, N. Cerletti and M. G. Grütter: The crystal structure of TGF- β 3 and comparison to TGF- β 2: implications for receptor binding. *Protein Sci*, 5(7), 1261-71 (1996)
17. A. P. Hinck, S. J. Archer, S. W. Qian, A. B. Roberts, M. B. Sporn, J. A. Weatherbee, M. L. Tsang, R. Lucas, B. L. Zhang, J. Wenker and D. A. Torchia: Transforming growth factor β 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor β 2. *Biochemistry*, 35(26), 8517-34 (1996)
18. S. Daopin, K. A. Piez, Y. Ogawa and D. R. Davies: Crystal structure of transforming growth factor- β 2: an unusual fold for the superfamily. *Science*, 257(5068), 369-73 (1992)
19. S. Radaev, Z. Zou, T. Huang, E. M. Lafer, A. P. Hinck and P. D. Sun: Ternary complex of TGF- β 1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily. *J Biol Chem*, 285(19), 14806-14 (2010)
20. E. P. Bottinger, J. J. Letterio and A. B. Roberts: Biology of TGF- β in knockout and transgenic mouse models. *Kidney Int*, 51(5), 1355-60 (1997)
21. A. B. Roberts and M. B. Sporn: Differential expression of the TGF- β isoforms in embryogenesis suggests specific roles in developing and adult tissues. *Mol Reprod Dev*, 32(2), 91-8 (1992)

22. F. Ramirez and D. B. Rifkin: Extracellular microfibrils: contextual platforms for TGF β and BMP signaling. *Curr Opin Cell Biol*, 21(5), 612-622 (2009)
23. R. O. Hynes: The extracellular matrix: not just pretty fibrils. *Science*, 326(5957), 1216-9 (2009)
24. G. Jenkins: The role of proteases in transforming growth factor- β activation. *Int J Biochem Cell Biol*, 40(6-7), 1068-1078 (2008)
25. J. P. Annes, J. S. Munger and D. B. Rifkin: Making sense of latent TGF- β activation. *Journal of Cell Science*, 116(2), 217-224 (2003)
26. P. J. Wipff and B. Hinz: Integrins and the activation of latent transforming growth factor β 1 - An intimate relationship. *Eur J Cell Biol* (2008)
27. J. E. Murphy-Ullrich and M. Poczatek: Activation of latent TGF- β by thrombospondin-1: mechanisms and physiology. *Cytokine Growth Factor Rev*, 11(1-2), 59-69 (2000)
28. S. L. Nishimura: Integrin-mediated transforming growth factor- β activation, a potential therapeutic target in fibrogenic disorders. *Am J Pathol* (2009)
29. P. Aluwihare and J. S. Munger: What the lung has taught us about latent TGF- β activation. *Am J Respir Cell Mol Biol*, 39(5), 499-502 (2008)
30. J. D. Thatcher: The TGF- β signal transduction pathway. *Sci Signal*, 3(119), tr4 (2010)
31. J. Massague and R. R. Gomis: The logic of TGF- β signaling. *FEBS Lett*, 580(12), 2811-20 (2006)
32. Y. Shi and J. Massague: Mechanisms of TGF- β signaling from cell membrane to the nucleus. *Cell*, 113(6), 685-700 (2003)
33. B. Schmierer and C. S. Hill: TGF β -Smad signal transduction: molecular specificity and functional flexibility. *Nat Rev Mol Cell Biol* (2007)
34. S. Ross and C. S. Hill: How the Smads regulate transcription. *Int J Biochem Cell Biol*, 40(3), 383-408 (2008)
35. M. Goumans, G. Valdimarsdottir, S. Itoh, A. Rosendahl, P. Sideras and P. ten Dijke: Balancing the activation state of the endothelium via two distinct TGF- β type I receptors. *Embo J*, 21(7), 1743-53 (2002)
36. M. J. Goumans, G. Valdimarsdottir, S. Itoh, F. Lebrin, J. Larsson, C. Mummery, S. Karlsson and P. ten Dijke: Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGF- β /ALK5 signaling. *Mol Cell*, 12(4), 817-28 (2003)
37. K. W. Finson, W. L. Parker, P. ten Dijke, M. Thorikay and A. Philip: ALK1 opposes ALK5/Smad3 signaling and expression of extracellular matrix components in human chondrocytes. *J Bone Miner Res*, 23(6), 896-906 (2008)
38. Y. E. Zhang: Non-Smad pathways in TGF- β signaling. *Cell Res*, 19, 128-139 (2008)
39. A. Moustakas and C. H. Heldin: Non-Smad TGF- β signals. *J Cell Sci*, 118(Pt 16), 3573-84 (2005)
40. R. Derynck and Y. E. Zhang: Smad-dependent and Smad-independent pathways in TGF- β family signalling. *Nature*, 425(6958), 577-84 (2003)
41. M. E. Dockrell, M. K. Phanish and B. M. Hendry: TGF- β auto-induction and connective tissue growth factor expression in human renal tubule epithelial cells requires N-ras. *Nephron Exp Nephrol*, 112(3), e71-9 (2009)
42. H. Nishi, T. Nakada, M. Hokamura, Y. Osakabe, O. Itokazu, L. E. Huang and K. Isaka: Hypoxia-inducible factor-1 transactivates transforming growth factor- β 3 in trophoblast. *Endocrinology*, 145(9), 4113-8 (2004)
43. H. Zhang, H. O. Akman, E. L. Smith, J. Zhao, J. E. Murphy-Ullrich and O. A. Batuman: Cellular response to hypoxia involves signaling via Smad proteins. *Blood*, 101(6), 2253-60 (2003)
44. L. Schaffer, A. Scheid, P. Spielmann, C. Breyman, R. Zimmermann, M. Meuli, M. Gassmann, H. H. Marti and R. H. Wenger: Oxygen-regulated expression of TGF- β 3, a growth factor involved in trophoblast differentiation. *Placenta*, 24(10), 941-50 (2003)
45. A. Scheid, R. H. Wenger, L. Schaffer, I. Camenisch, O. Distler, A. Ferenc, H. Cristina, H. E. Ryan, R. S. Johnson, K. F. Wagner, U. G. Stauffer, C. Bauer, M. Gassmann and M. Meuli: Physiologically low oxygen concentrations in fetal skin regulate hypoxia-inducible factor 1 and transforming growth factor- β 3. *Faseb J*, 16(3), 411-3 (2002)
46. P. M. Villiger and M. Lotz: Differential expression of TGF β isoforms by human articular chondrocytes in response to growth factors. *J Cell Physiol*, 151(2), 318-25 (1992)
47. S. J. Kim, P. Angel, R. Lafyatis, K. Hattori, K. Y. Kim, M. B. Sporn, M. Karin and A. B. Roberts: Autoinduction of transforming growth factor β 1 is mediated by the AP-1 complex. *Mol Cell Biol*, 10(4), 1492-7 (1990)
48. D. J. Grainger, C. D. Byrne, C. M. Witchell and J. C. Metcalfe: Transforming growth factor β is sequestered into an inactive pool by lipoproteins. *J Lipid Res*, 38(11), 2344-52 (1997)
49. S. Hagiwara, Y. Murakumo, S. Mii, T. Shigetomi, N. Yamamoto, H. Furue, M. Ueda and M. Takahashi:

Processing of CD109 by furin and its role in the regulation of TGF- β signaling. *Oncogene*, 29(15), 2181-91 (2010)

50. A. Hockla, D. C. Radisky and E. S. Radisky: Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. *Breast Cancer Res Treat* (2009)

51. C. Bernabeu, J. M. Lopez-Novoa and M. Quintanilla: The emerging role of TGF- β superfamily co-receptors in cancer. *Biochim Biophys Acta*, 1792(10), 954-73 (2009)

52. M. Hasegawa, S. Moritani, Y. Murakumo, T. Sato, S. Hagiwara, C. Suzuki, S. Mii, M. Jijiwa, A. Enomoto, N. Asai, S. Ichihara and M. Takahashi: CD109 expression in basal-like breast carcinoma. *Pathol Int*, 58(5), 288-94 (2008)

53. E. Pardali and P. ten Dijke: Transforming growth factor- β signaling and tumor angiogenesis. *Front Biosci*, 14, 4848-61 (2009)

54. P. ten Dijke, M. J. Goumans and E. Pardali: Endoglin in angiogenesis and vascular diseases. *Angiogenesis*, 11(1), 79-89 (2008)

55. C. E. Gatz, S. Y. Oh and G. C. Blobe: Roles for the type III TGF- β receptor in human cancer. *Cell Signal*, 22(8), 1163-74 (2010)

56. S. McLean and G. M. Di Guglielmo: T β RIII directs clathrin-mediated endocytosis of TGF β type I and II receptors. *Biochem J*, 429(1), 137-145 (2010)

57. E. C. Finger, N. Y. Lee, H. J. You and G. C. Blobe: Endocytosis of the type III TGF- β receptor through the clathrin-independent/lipid raft pathway regulates TGF- β signaling and receptor downregulation. *J Biol Chem*, 283(50), 34808-18 (2008)

58. C. Santander and E. Brandan: Betaglycan induces TGF- β signaling in a ligand-independent manner, through activation of the p38 pathway. *Cell Signal*, 18(9), 1482-91 (2006)

59. H. J. You, M. W. Bruinsma, T. How, J. H. Ostrander and G. C. Blobe: The type III TGF- β receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. *Carcinogenesis*, 28(12), 2491-2500 (2007)

60. W. Chen, K. C. Kirkbride, T. How, C. D. Nelson, J. Mo, J. P. Frederick, X. F. Wang, R. J. Lefkowitz and G. C. Blobe: β -arrestin 2 mediates endocytosis of type III TGF- β receptor and down-regulation of its signaling. *Science*, 301(5638), 1394-7 (2003)

61. K. R. Solomon, P. Sharma, M. Chan, P. T. Morrison and R. W. Finberg: CD109 represents a novel branch of the α 2-macroglobulin/complement gene family. *Gene*, 327(2), 171-183 (2004)

62. M. Hashimoto, M. Ichihara, T. Watanabe, K. Kawai, K. Koshikawa, N. Yuasa, T. Takahashi, Y. Yatabe, Y. Murakumo, J.-m. Zhang, Y. Nimura and M. Takahashi: Expression of CD109 in human cancer. *Oncogene*, 23(20), 3716-3720 (2004)

63. A. C. Schuh, N. A. Watkins, Q. Nguyen, N. J. Harmer, M. Lin, J. Y. A. Prosper, K. Campbell, D. R. Sutherland, P. Metcalfe, W. Horsfall and W. H. Ouwehand: A tyrosine703serine polymorphism of CD109 defines the Gov platelet alloantigens. *Blood*, 99(5), 1692-1698 (2002)

64. M. Lin, D. R. Sutherland, W. Horsfall, N. Totty, E. Yeo, R. Nayar, X.-F. Wu and A. C. Schuh: Cell surface antigen CD109 is a novel member of the alpha 2 macroglobulin/C3, C4, C5 family of thioester-containing proteins. *Blood*, 99(5), 1683-1691 (2002)

65. K. W. Finnson, B. Y. Tam, K. Liu, A. Marcoux, P. Lepage, S. Roy, A. A. Bizet and A. Philip: Identification of CD109 as part of the TGF- β receptor system in human keratinocytes. *FASEB J*, 20(9), 1525-7 (2006)

66. A. Bizet, K. Liu, N. Tran-Khanh, A. Saksena, J. Vorstenbosch, K. Finnson, M. Buschmann and A. Philip: The TGF- β co-receptor, CD109, promotes internalization and degradation of TGF- β receptors. *BBA-Molecular Cell Research*: accepted for publication (2010)

67. Y. Ohshima, I. Yajima, M. Y. Kumasaka, T. Yanagishita, D. Watanabe, M. Takahashi, Y. Inoue, H. Ihn, Y. Matsumoto and M. Kato: CD109 expression levels in malignant melanoma. *J Dermatol Sci* (2009)

68. S. Hagiwara, Y. Murakumo, T. Sato, T. Shigetom, K. Mitsudo, I. Tohnai, M. Ueda and M. Takahashi: Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. *Cancer Science*, 99(10), 1916-1923 (2008)

69. T. Sato, Y. Murakumo, S. Hagiwara, M. Jijiwa, C. Suzuki, Y. Yatabe and M. Takahashi: High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. *Pathology International*, 57, 719-724 (2007)

70. J. M. Zhang, M. Hashimoto, K. Kawai, Y. Murakumo, T. Sato, M. Ichihara, S. Nakamura and M. Takahashi: CD109 expression in squamous cell carcinoma of the uterine cervix. *Pathol Int*, 55(4), 165-9 (2005)

71. K. H. Wrighton, X. Lin and X. H. Feng: Phospho-control of TGF- β superfamily signaling. *Cell Res*, 19(1), 8-20 (2009)

72. X. Yan, Z. Liu and Y. Chen: Regulation of TGF- β signaling by Smad7. *Acta Biochim Biophys Sin (Shanghai)*, 41(4), 263-72 (2009)

73. Y. Inoue and T. Imamura: Regulation of TGF- β family signaling by E3 ubiquitin ligases. *Cancer Sci* (2008)

74. G. Valdimarsdottir, M. J. Goumans, F. Itoh, S. Itoh, C. H. Heldin and P. ten Dijke: Smad7 and protein phosphatase 1 α are critical determinants in the duration of TGF- β /ALK1 signaling in endothelial cells. *BMC Cell Biol*, 7, 16 (2006)
75. A. M. Bhosale and J. B. Richardson: Articular cartilage: structure, injuries and review of management. *Br Med Bull*, 87, 77-95 (2008)
76. D. R. Eyre: Collagens and cartilage matrix homeostasis. *Clin Orthop Relat Res*(427 Suppl), S118-22 (2004)
77. D. R. Eyre, M. A. Weis and J. J. Wu: Articular cartilage collagen: an irreplaceable framework? *Eur Cell Mater*, 12, 57-63 (2006)
78. D. Heinegard: Proteoglycans and more--from molecules to biology. *Int J Exp Pathol*, 90(6), 575-86 (2009)
79. M. B. Goldring, K. Tsuchimochi and K. Ijiri: The control of chondrogenesis. *J Cell Biochem*, 97(1), 33-44 (2006)
80. I. Onyekwelu, M. B. Goldring and C. Hidaka: Chondrogenesis, joint formation, and articular cartilage regeneration. *J Cell Biochem*, 107(3), 383-92 (2009)
81. Y. Kawakami, J. Rodriguez-Leon and J. C. Izpisua Belmonte: The role of TGF- β s and Sox9 during limb chondrogenesis. *Curr Opin Cell Biol*, 18(6), 723-9 (2006)
82. L. Quintana, N. I. zur Nieden and C. E. Semino: Morphogenetic and regulatory mechanisms during developmental chondrogenesis: new paradigms for cartilage tissue engineering. *Tissue Eng Part B Rev*, 15(1), 29-41 (2009)
83. X. Yang, L. Chen, X. Xu, C. Li, C. Huang and C.-X. Deng: TGF- β /Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. *J. Cell Biol.*, 153(1), 35-46 (2001)
84. E. M. Darling and K. A. Athanasiou: Articular cartilage bioreactors and bioprocesses. *Tissue Eng*, 9(1), 9-26 (2003)
85. B. Vanwanseele, F. Eckstein, H. Knecht, E. Stussi and A. Spaepen: Knee cartilage of spinal cord-injured patients displays progressive thinning in the absence of normal joint loading and movement. *Arthritis Rheum*, 46(8), 2073-8 (2002)
86. S. B. Abramson and M. Attur: Developments in the scientific understanding of osteoarthritis. *Arthritis Res Ther*, 11(3), 227 (2009)
87. M. A. Adams, P. Dolan and D. S. McNally: The internal mechanical functioning of intervertebral discs and articular cartilage, and its relevance to matrix biology. *Matrix Biol*, 28(7), 384-9 (2009)
88. P. Malaviya and R. M. Nerem: Fluid-induced shear stress stimulates chondrocyte proliferation partially mediated via TGF- β 1. *Tissue Eng*, 8(4), 581-90 (2002)
89. C. P. Neu, A. Khalafi, K. Komvopoulos, T. M. Schmid and A. H. Reddi: Mechanotransduction of bovine articular cartilage superficial zone protein by transforming growth factor β signaling. *Arthritis Rheum*, 56(11), 3706-14 (2007)
90. E. J. Koay, G. Ofek and K. A. Athanasiou: Effects of TGF- β 1 and IGF-I on the compressibility, biomechanics, and strain-dependent recovery behavior of single chondrocytes. *J Biomech*, 41(5), 1044-52 (2008)
91. G. DuRaine, C. P. Neu, S. M. Chan, K. Komvopoulos, R. K. June and A. H. Reddi: Regulation of the friction coefficient of articular cartilage by TGF- β 1 and IL-1 β . *J Orthop Res*, 27(2), 249-56 (2009)
92. R. L. Mauck, S. B. Nicoll, S. L. Seyhan, G. A. Ateshian and C. T. Hung: Synergistic action of growth factors and dynamic loading for articular cartilage tissue engineering. *Tissue Eng*, 9(4), 597-611 (2003)
93. E. G. Lima, L. Bian, K. W. Ng, R. L. Mauck, B. A. Byers, R. S. Tuan, G. A. Ateshian and C. T. Hung: The beneficial effect of delayed compressive loading on tissue-engineered cartilage constructs cultured with TGF- β 3. *Osteoarthritis Cartilage*, 15(9), 1025-33 (2007)
94. E. G. Lima, L. Bian, R. L. Mauck, B. A. Byers, R. S. Tuan, G. A. Ateshian and C. T. Hung: The effect of applied compressive loading on tissue-engineered cartilage constructs cultured with TGF- β 3. *Conf Proc IEEE Eng Med Biol Soc*, 1, 779-82 (2006)
95. J. Chimal-Monroy and L. Diaz de Leon: Differential effects of transforming growth factors β 1, β 2, β 3 and β 5 on chondrogenesis in mouse limb bud mesenchymal cells. *Int J Dev Biol*, 41(1), 91-102 (1997)
96. M. E. Joyce, A. B. Roberts, M. B. Sporn and M. E. Bolander: Transforming growth factor- β and the initiation of chondrogenesis and osteogenesis in the rat femur. *J Cell Biol*, 110(6), 2195-207 (1990)
97. H. L. Glansbeek, H. M. van Beuningen, E. L. Vitters, P. M. van der Kraan and W. B. van den Berg: Stimulation of articular cartilage repair in established arthritis by local administration of transforming growth factor- β into murine knee joints. *Lab Invest*, 78(2), 133-42 (1998)
98. E. B. Hunziker: Growth-factor-induced healing of partial-thickness defects in adult articular cartilage. *Osteoarthritis Cartilage*, 9(1), 22-32 (2001)
99. E. B. Hunziker and L. C. Rosenberg: Repair of partial-thickness defects in articular cartilage: cell recruitment from the synovial membrane. *J Bone Joint Surg Am*, 78(5), 721-33 (1996)

100. A. Scharstuhl, H. L. Glansbeek, H. M. van Beuningen, E. L. Vitters, P. M. van der Kraan and W. B. van den Berg: Inhibition of endogenous TGF- β during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. *J Immunol*, 169(1), 507-514 (2002)
101. R. Serra, M. Johnson, E. H. Filvaroff, J. LaBorde, D. M. Sheehan, R. Derynck and H. L. Moses: Expression of a truncated, kinase-defective TGF- β type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. *J. Cell Biol.*, 139(2), 541-552 (1997)
102. T. F. Li, M. Darowish, M. J. Zuscik, D. Chen, E. M. Schwarz, R. N. Rosier, H. Drissi and R. J. O'Keefe: Smad3-deficient chondrocytes have enhanced BMP signaling and accelerated differentiation. *J Bone Miner Res*, 21(1), 4-16 (2006)
103. E. N. Blaney Davidson, E. L. Vitters, P. M. van der Kraan and W. B. van den Berg: Expression of transforming growth factor- β (TGF β) and the TGF β signalling molecule Smad-2P in spontaneous and instability-induced osteoarthritis: role in cartilage degradation, chondrogenesis and osteophyte formation. *Ann Rheum Dis*, 65(11), 1414-1421 (2006)
104. J. Loughlin: The genetic epidemiology of human primary osteoarthritis: current status. *Expert Rev Mol Med*, 7(9), 1-12 (2005)
105. S. Ikegawa: New gene associations in osteoarthritis: what do they provide, and where are we going? *Curr Opin Rheumatol*, 19(5), 429-34 (2007)
106. S. Ikegawa: Expression, regulation and function of asporin, a susceptibility gene in common bone and joint diseases. *Curr Med Chem*, 15(7), 724-8 (2008)
107. J. Dai and S. Ikegawa: Recent advances in association studies of osteoarthritis susceptibility genes. *J Hum Genet*, 55(2), 77-80 (2010)
108. H. M. van Beuningen, P. M. van der Kraan, O. J. Arntz and W. B. van den Berg: Transforming growth factor- β 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. *Lab Invest*, 71(2), 279-90 (1994)
109. H. M. van Beuningen, H. L. Glansbeek, P. M. van der Kraan and W. B. van den Berg: Osteoarthritis-like changes in the murine knee joint resulting from intra-articular transforming growth factor- β injections. *Osteoarthritis Cartilage*, 8(1), 25-33 (2000)
110. A. C. Bakker, F. A. van de Loo, H. M. van Beuningen, P. Sime, P. L. van Lent, P. M. van der Kraan, C. D. Richards and W. B. van den Berg: Overexpression of active TGF- β 1 in the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte formation. *Osteoarthritis Cartilage*, 9(2), 128-36 (2001)
111. M. J. Alcaraz, J. Megias, I. Garcia-Arnanidis, V. Clerigues and M. I. Guillen: New molecular targets for the treatment of osteoarthritis. *Biochem Pharmacol*, 80(1), 13-21 (2010)
112. M. B. Goldring and S. R. Goldring: Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. *Ann N Y Acad Sci*, 1192(1), 230-7 (2010)
113. A. Shane Anderson and R. F. Loeser: Why is osteoarthritis an age-related disease? *Best Pract Res Clin Rheumatol*, 24(1), 15-26 (2010)
114. J. Martel-Pelletier and J. P. Pelletier: Is osteoarthritis a disease involving only cartilage or other articular tissues? *Eklem Hastalik Cerrahisi*, 21(1), 2-14 (2010)
115. H. B. Sun: Mechanical loading, cartilage degradation, and arthritis. *Ann N Y Acad Sci*, 1211(1), 37-50 (2010)
116. S. R. Goldring and M. B. Goldring: Bone and cartilage in osteoarthritis: is what's best for one good or bad for the other? *Arthritis Res Ther*, 12(5), 143 (2010)
117. Y. Henrotin, L. Pesesse and C. Sanchez: Subchondral bone in osteoarthritis physiopathology: state-of-the-art and perspectives. *Biomed Mater Eng*, 19(4-5), 311-6 (2009)
118. J. Wu, W. Liu, A. Bemis, E. Wang, Y. Qiu, E. A. Morris, C. R. Flannery and Z. Yang: Comparative proteomic characterization of articular cartilage tissue from normal donors and patients with osteoarthritis. *Arthritis Rheum*, 56(11), 3675-84 (2007)
119. M. P. Verdier, S. Seite, K. Guntzer, J. P. Pujol and K. Boumediene: Immunohistochemical analysis of transforming growth factor β isoforms and their receptors in human cartilage from normal and osteoarthritic femoral heads. *Rheumatol Int*, 25(2), 118-24 (2005)
120. K. Boumediene, T. Conrozier, P. Mathieu, M. Richard, C. Marcelli, E. Vignon and J. P. Pujol: Decrease of cartilage transforming growth factor- β receptor II expression in the rabbit experimental osteoarthritis-potential role in cartilage breakdown. *Osteoarthritis Cartilage*, 6(2), 146-9 (1998)
121. J. Xiao, T. Li, Z. Wu, Z. Shi, J. Chen, S. K. Lam, Z. Zhao, L. Yang and G. Qiu: REST corepressor (CoREST) repression induces phenotypic gene regulation in advanced osteoarthritic chondrocytes. *J Orthop Res*, 28(12), 1569-75 (2010)
122. M. Pombo-Suarez, M. T. Castano-Oreja, M. Calaza, J. J. Gomez-Reino and A. Gonzalez: Differential up-regulation of the three TGF- β isoforms in human osteoarthritic cartilage. *Ann Rheum Dis*, 68(4), 568-71 (2009)
123. M. Nakajima, H. Kizawa, M. Saitoh, I. Kou, K. Miyazono and S. Ikegawa: Mechanisms for asporin

- function and regulation in articular cartilage. *J. Biol. Chem.*, 282(44), 32185-92 (2007)
124. C. T. Appleton, V. Pitelka, J. Henry and F. Beier: Global analyses of gene expression in early experimental osteoarthritis. *Arthritis Rheum*, 56(6), 1854-68 (2007)
125. J. P. Pujol, C. Chadjichristos, F. Legendre, C. Bauge, G. Beauchef, R. Andriamanalijaona, P. Galera and K. Boumediene: Interleukin-1 and transforming growth factor- β 1 as crucial factors in osteoarthritic cartilage metabolism. *Connect Tissue Res*, 49(3), 293-7 (2008)
126. T. Wei, N. H. Kulkarni, Q. Q. Zeng, L. M. Helvering, X. Lin, F. Lawrence, L. Hale, M. G. Chambers, C. Lin, A. Harvey, Y. L. Ma, R. L. Cain, J. Oskins, M. A. Carozza, D. D. Edmondson, T. Hu, R. R. Miles, T. P. Ryan, J. E. Onyia and P. G. Mitchell: Analysis of early changes in the articular cartilage transcriptome in the rat meniscal tear model of osteoarthritis: pathway comparisons with the rat anterior cruciate transection model and with human osteoarthritic cartilage. *Osteoarthritis Cartilage*, 18(7), 992-1000 (2010)
127. T. Aigner, K. Fundel, J. Saas, P. M. Gebhard, J. Haag, T. Weiss, A. Zien, F. Obermayr, R. Zimmer and E. Bartnik: Large-scale gene expression profiling reveals major pathogenetic pathways of cartilage degeneration in osteoarthritis. *Arthritis Rheum*, 54(11), 3533-44 (2006)
128. B. Dabovic, Y. Chen, C. Colarossi, H. Obata, L. Zambuto, M. A. Perle and D. B. Rifkin: Bone abnormalities in latent TGF- β binding protein (LTBP)-3-null mice indicate a role for LTBP-3 in modulating TGF- β bioavailability. *J Cell Biol*, 156(2), 227-32 (2002)
129. B. Dabovic, Y. Chen, C. Colarossi, L. Zambuto, H. Obata and D. B. Rifkin: Bone defects in latent TGF- β binding protein (LTBP)-3 null mice; a role for LTBP in TGF- β presentation. *J Endocrinol*, 175(1), 129-41 (2002)
130. K. Johnson, S. Hashimoto, M. Lotz, K. Pritzker and R. Terkeltaub: Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. *Am J Pathol*, 159(1), 149-63 (2001)
131. D. Heinkel, C. M. Gohr, M. Uzuki and A. K. Rosenthal: Transglutaminase contributes to CPPD crystal formation in osteoarthritis. *Front Biosci*, 9, 3257-61 (2004)
132. A. Orlandi, F. Oliva, G. Taurisano, E. Candi, A. Di Lascio, G. Melino, L. G. Spagnoli and U. Tarantino: Transglutaminase-2 differently regulates cartilage destruction and osteophyte formation in a surgical model of osteoarthritis. *Amino Acids*, 36(4), 755-63 (2009)
133. J. L. Huebner, K. A. Johnson, V. B. Kraus and R. A. Terkeltaub: Transglutaminase 2 is a marker of chondrocyte hypertrophy and osteoarthritis severity in the Hartley guinea pig model of knee OA. *Osteoarthritis Cartilage*, 17(8), 1056-64 (2009)
134. D. Pfander, T. Cramer, D. Deuerling, G. Weseloh and B. Swoboda: Expression of thrombospondin-1 and its receptor CD36 in human osteoarthritic cartilage. *Ann Rheum Dis*, 59(6), 448-54 (2000)
135. M. G. Attur, G. D. Palmer, H. E. Al-Mussawir, M. Dave, C. C. Teixeira, D. B. Rifkin, C. T. Appleton, F. Beier and S. B. Abramson: F-spondin, a neuroregulatory protein, is up-regulated in osteoarthritis and regulates cartilage metabolism via TGF- β activation. *Faseb J*, 23(1), 79-89 (2009)
136. C. Karlsson, T. Dehne, A. Lindahl, M. Brittberg, A. Pruss, M. Sittertinger and J. Ringe: Genome-wide expression profiling reveals new candidate genes associated with osteoarthritis. *Osteoarthritis Cartilage*, 18(4), 581-92 (2010)
137. I. M. Jou, A. L. Shiau, S. Y. Chen, C. R. Wang, D. B. Shieh, C. S. Tsai and C. L. Wu: Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis. *Arthritis Rheum*, 52(1), 339-44 (2005)
138. J. L. Hsieh, P. C. Shen, A. L. Shiau, I. M. Jou, C. H. Lee, C. R. Wang, M. L. Teo and C. L. Wu: Intra-articular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis. *J Orthop Res* (2010)
139. M. H. Barcellos-Hoff and T. A. Dix: Redox-mediated activation of latent transforming growth factor- β 1. *Mol Endocrinol*, 10(9), 1077-83 (1996)
140. V. B. Kraus, J. L. Huebner, T. Stabler, C. M. Flahiff, L. A. Setton, C. Fink, V. Vilim and A. G. Clark: Ascorbic acid increases the severity of spontaneous knee osteoarthritis in a guinea pig model. *Arthritis Rheum*, 50(6), 1822-31 (2004)
141. T. Hayami, M. Pickarski, G. A. Wesolowski, J. McLane, A. Bone, J. Destefano, G. A. Rodan and T. Duong le: The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. *Arthritis Rheum*, 50(4), 1193-206 (2004)
142. T. Dehne, C. Karlsson, J. Ringe, M. Sittertinger and A. Lindahl: Chondrogenic differentiation potential of osteoarthritic chondrocytes and their possible use in matrix-associated autologous chondrocyte transplantation. *Arthritis Res Ther*, 11(5), R133 (2009)
143. E. N. Blaney Davidson, D. F. Remst, E. L. Vitters, H. M. van Beuningen, A. B. Blom, M. J. Goumans, W. B. van den Berg and P. M. van der Kraan: Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice. *J Immunol*, 182(12), 7937-45 (2009)

144. M. A. Gomez-Camarillo and J. B. Kouri: Ontogeny of rat chondrocyte proliferation: studies in embryo, adult and osteoarthritic (OA) cartilage. *Cell Res*, 15(2), 99-104 (2005)
145. E. N. Blaney Davidson, A. Scharstuhl, E. L. Vitters, P. M. van der Kraan and W. B. van den Berg: Reduced transforming growth factor- β signaling in cartilage of old mice: role in impaired repair capacity. *Arthritis Res Ther*, 7(6), R1338-47 (2005)
146. Q. Wu, J. H. Huang, E. R. Sampson, K. O. Kim, M. J. Zuscik, R. J. O'Keefe, D. Chen and R. N. Rosier: Smurf2 induces degradation of GSK-3 β and upregulates β -catenin in chondrocytes: a potential mechanism for Smurf2-induced degeneration of articular cartilage. *Exp Cell Res* (2009)
147. C. G. Li, Q. Q. Liang, Q. Zhou, E. Menga, X. J. Cui, B. Shu, C. J. Zhou, Q. Shi and Y. J. Wang: A continuous observation of the degenerative process in the intervertebral disc of Smad3 gene knock-out mice. *Spine (Phila Pa 1976)*, 34(13), 1363-9 (2009)
148. J. Y. Yao, Y. Wang, J. An, C. M. Mao, N. Hou, Y. X. Lv, Y. L. Wang, F. Cui, M. Huang and X. Yang: Mutation analysis of the Smad3 gene in human osteoarthritis. *Eur J Hum Genet*, 11(9), 714-7 (2003)
149. A. M. Valdes, T. D. Spector, A. Tamm, K. Kisand, S. A. Doherty, E. M. Dennison, M. Mangino, I. Kerna, D. J. Hart, M. Wheeler, C. Cooper, R. J. Lories, N. K. Arden and M. Doherty: Genetic variation in the Smad3 gene is associated with hip and knee osteoarthritis. *Arthritis Rheum*, 62(8), 2347-2352 (2010)
150. J. Pannu, S. Nakerakanti, E. Smith, P. t. Dijke and M. Trojanowska: Transforming growth factor- β receptor type I dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. *J. Biol. Chem.*, 282(14), 10405-10413 (2007)
151. U. Valcourt, J. Gouttenoire, A. Moustakas, D. Herbage and F. Mallein-Gerin: Functions of transforming growth factor- β family type I receptors and Smad proteins in the hypertrophic maturation and osteoblastic differentiation of chondrocytes. *J Biol Chem*, 277(37), 33545-58 (2002)
152. B. Bau, J. Haag, E. Schmid, M. Kaiser, P. M. Gebhard and T. Aigner: Bone morphogenetic protein-mediating receptor-associated Smads as well as common Smad are expressed in human articular chondrocytes but not up-regulated or down-regulated in osteoarthritic cartilage. *J Bone Miner Res*, 17(12), 2141-50 (2002)
153. S. Otsuki, S. R. Hanson, S. Miyaki, S. P. Grogan, M. Kinoshita, H. Asahara, C. H. Wong and M. K. Lotz: Extracellular sulfatases support cartilage homeostasis by regulating BMP and FGF signaling pathways. *Proc Natl Acad Sci U S A*, 107(22), 10202-7 (2010)
154. S. Otsuki, N. Taniguchi, S. P. Grogan, D. D'Lima, M. Kinoshita and M. Lotz: Expression of novel extracellular sulfatases Sulf-1 and Sulf-2 in normal and osteoarthritic articular cartilage. *Arthritis Res Ther*, 10(3), R61 (2008)
155. M. Kaiser, J. Haag, S. Soder, B. Bau and T. Aigner: Bone morphogenetic protein and transforming growth factor beta inhibitory Smads 6 and 7 are expressed in human adult normal and osteoarthritic cartilage *in vivo* and are differentially regulated *in vitro* by interleukin-1 β . *Arthritis Rheum*, 50(11), 3535-40 (2004)
156. C. Bauge, J. Attia, S. Leclercq, J. P. Pujol, P. Galera and K. Boumediene: Interleukin-1 β up-regulation of Smad7 via NF-kappaB activation in human chondrocytes. *Arthritis Rheum*, 58(1), 221-6 (2008)
157. C. Bauge, F. Legendre, S. Leclercq, J. M. Elissalde, J. P. Pujol, P. Galera and K. Boumediene: Interleukin-1 β impairment of transforming growth factor β 1 signaling by down-regulation of transforming growth factor β receptor type II and up-regulation of Smad7 in human articular chondrocytes. *Arthritis Rheum*, 56(9), 3020-32 (2007)
158. J. A. Roman-Blas, D. G. Stokes and S. A. Jimenez: Modulation of TGF- β signaling by proinflammatory cytokines in articular chondrocytes. *Osteoarthritis Cartilage*, 15(12), 1367-77 (2007)
159. R. F. Loeser: Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrix. *Osteoarthritis Cartilage*, 17(8), 971-9 (2009)
160. Q. Wu, K. O. Kim, E. R. Sampson, D. Chen, H. Awad, T. O'Brien, J. E. Puzas, H. Drissi, E. M. Schwarz, R. J. O'Keefe, M. J. Zuscik and R. N. Rosier: Induction of an osteoarthritis-like phenotype and degradation of phosphorylated Smad3 by Smurf2 in transgenic mice. *Arthritis Rheum*, 58(10), 3132-3144 (2008)
161. F. Beier and R. F. Loeser: Biology and pathology of Rho GTPase, PI-3 kinase-Akt, and MAP kinase signaling pathways in chondrocytes. *J Cell Biochem*, 110(3), 573-80 (2010)
162. L. M. Gunnell, J. H. Jonason, A. E. Loisel, A. Kohn, E. M. Schwarz, M. J. Hilton and R. J. O'Keefe: TAK1 regulates cartilage and joint development via the MAPK and BMP signaling pathways. *J Bone Miner Res*, 25(8), 1784-97 (2010)
163. B. Qiao, S. R. Padilla and P. D. Benay: TGF- β activated kinase 1 (TAK1) mimics and mediates TGF- β -induced stimulation of type II collagen synthesis in chondrocytes independent of Col2a1 transcription and Smad3 signaling. *J. Biol. Chem.*, 280(17), 17562-71 (2005)
164. A. M. Ionescu, E. M. Schwarz, M. J. Zuscik, H. Drissi, J. E. Puzas, R. N. Rosier and R. J. O'Keefe: ATF-2 cooperates with Smad3 to mediate TGF- β effects on chondrocyte maturation. *Exp Cell Res*, 288(1), 198-207 (2003)
165. A. Leask: Targeting the TGF β , endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. *Cell Signal*, 20(8), 1409-14 (2008)

166. W. L. Parker, M. B. Goldring and A. Philip: Endoglin is expressed on human chondrocytes and forms a heteromeric complex with betaglycan in a ligand and type II TGF β receptor independent manner. *J Bone Miner Res*, 18(2), 289-302 (2003)
167. K. W. Finnsen, W. L. Parker, Y. Chi, C. Hoemann, M. B. Goldring, J. Antoniou and A. Philip: Endoglin differentially regulates TGF- β -induced Smad2/3 and Smad1/5 signalling and its expression correlates with extracellular matrix production and cellular differentiation state in human chondrocytes. *Osteoarthritis Cartilage*, 18(11), 1518-27 (2010)
168. S. Honsawek, A. Tanavalee and P. Yuktanandana: Elevated circulating and synovial fluid endoglin are associated with primary knee osteoarthritis severity. *Arch Med Res*, 40(7), 590-4 (2009)
169. K. Tsuritani, J. Takeda, J. Sakagami, A. Ishii, T. Eriksson, T. Hara, H. Ishibashi, Y. Koshihara, K. Yamada and Y. Yoneda: Cytokine receptor-like factor 1 is highly expressed in damaged human knee osteoarthritic cartilage and involved in osteoarthritis downstream of TGF- β . *Calcif Tissue Int*, 86(1), 47-57 (2010)
170. F. Dell'accio, C. De Bari, N. M. Eltawil, P. Vanhummelen and C. Pitzalis: Identification of the molecular response of articular cartilage to injury, by microarray screening: Wnt-16 expression and signaling after injury and in osteoarthritis. *Arthritis Rheum*, 58(5), 1410-21 (2008)
171. R. Rollin, R. Alvarez-Lafuente, F. Marco, J. A. Garcia-Asenjo, J. A. Jover, L. Rodriguez, L. Lopez-Duran and B. Fernandez-Gutierrez: Abnormal transforming growth factor- β expression in mesenchymal stem cells from patients with osteoarthritis. *J Rheumatol* (2008)
172. E. Sanchez-Sabate, L. Alvarez, E. Gil-Garay, L. Munuera and N. Vilaboa: Identification of differentially expressed genes in trabecular bone from the iliac crest of osteoarthritic patients. *Osteoarthritis Cartilage*, 17(8), 1106-14 (2009)
173. A. Bizet, K. Liu, N. Tran-Khanh, A. Saksena, K. Finnsen, M. Buschmann and A. Philip: CD109, a TGF- β coreceptor, regulates TGF- β receptor internalization and degradation in keratinocytes. In: *16th Annual Meeting of the Society for Investigative Dermatology*. Ed P. Bergstresser. The Journal of Investigative Dermatology, Nature Publishing Group, Montreal, QC, Canada (2009)
174. M. Polacek, J. A. Bruun, O. Johansen and I. Martinez: Differences in the secretome of cartilage explants and cultured chondrocytes unveiled by SILAC technology. *J Orthop Res*, 28(8), 1040-1049 (2010)
175. A. L. Stevens, J. S. Wishnok, D. H. Chai, A. J. Grodzinsky and S. R. Tannenbaum: A sodium dodecyl sulfate-polyacrylamide gel electrophoresis-liquid chromatography tandem mass spectrometry analysis of bovine cartilage tissue response to mechanical compression injury and the inflammatory cytokines tumor necrosis factor- α and interleukin-1 β . *Arthritis Rheum*, 58(2), 489-500 (2008)
176. P. K. Dagur, G. Tatlici, M. Gourley, L. Samsel, N. Raghavachari, P. Liu, D. Liu and J. P. McCoy, Jr.: CD146+ T lymphocytes are increased in both the peripheral circulation and in the synovial effusions of patients with various musculoskeletal diseases and display pro-inflammatory gene profiles. *Cytometry B Clin Cytom*, 78B, 88-95 (2010)
177. A. Yoshimura, Y. Wakabayashi and T. Mori: Cellular and molecular basis for the regulation of inflammation by TGF- β . *J Biochem* (2010)
178. X. H. Feng and R. Derynck: Specificity and versatility in TGF- β signaling through Smads. *Annu Rev Cell Dev Biol*, 21, 659-93 (2005)
179. C. Man, S. Zhu, B. Zhang and J. Hu: Protection of articular cartilage from degeneration by injection of transforming growth factor- β in temporomandibular joint osteoarthritis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, 108(3), 335-40 (2009)
180. H. M. van Beuningen, P. M. van der Kraan, O. J. Arntz and W. B. van den Berg: *In vivo* protection against interleukin-1-induced articular cartilage damage by transforming growth factor- β 1: age-related differences. *Ann Rheum Dis*, 53(9), 593-600 (1994)
181. H. M. van Beuningen, P. M. van der Kraan, O. J. Arntz and W. B. van den Berg: Protection from interleukin 1 induced destruction of articular cartilage by transforming growth factor β : studies in anatomically intact cartilage *in vitro* and *in vivo*. *Ann Rheum Dis*, 52(3), 185-91 (1993)
182. A. Scharstuhl, E. L. Vitters, P. M. van der Kraan and W. B. van den Berg: Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor β /bone morphogenetic protein inhibitors during experimental osteoarthritis. *Arthritis Rheum*, 48(12), 3442-51 (2003)
183. E. N. Blaney Davidson, E. L. Vitters, W. B. van den Berg and P. M. van der Kraan: TGF β -induced cartilage repair is maintained but fibrosis is blocked in the presence of Smad7. *Arthritis Res Ther*, 8(3), R65 (2006)
184. M. M. Vilchis-Landeros, J. L. Montiel, V. Mendoza, G. Mendoza-Hernandez and F. Lopez-Casillas: Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor- β neutralizing agent. *Biochem J*, 355(Pt 1), 215-22 (2001)
185. S. Venkatesha, M. Toporsian, C. Lam, J. Hanai, T. Mammoto, Y. M. Kim, Y. Bdoah, K. H. Lim, H. T. Yuan, T. A. Libermann, I. E. Stillman, D. Roberts, P. A. D'Amore, F. H. Epstein, F. W. Sellke, R. Romero, V. P. Sukhatme, M. Letarte and S. A. Karumanchi: Soluble

endoglin contributes to the pathogenesis of preeclampsia. *Nat Med*, 12(6), 642-9 (2006)

186. B. Tam, D. Larouche, L. Germain, N. Hooper and A. Philip: Characterization of a 150 kDa accessory receptor for TGF- β 1 on keratinocytes: direct evidence for a GPI anchor and ligand binding of the released form. *Journal of Cellular Biochemistry*, 83, 494-507 (2001)

187. T. Schubert, S. Kaufmann, A. K. Wenke, S. Grassel and A. K. Bosserhoff: Role of deleted in colon carcinoma in osteoarthritis and in chondrocyte migration. *Rheumatology (Oxford)*, 48(11), 1435-41 (2009)

188. C. L. Murphy: HIF-2 α - a mediator of osteoarthritis? *Cell Res*, 20(9), 977-9 (2010)

189. T. Saito, A. Fukai, A. Mabuchi, T. Ikeda, F. Yano, S. Ohba, N. Nishida, T. Akune, N. Yoshimura, T. Nakagawa, K. Nakamura, K. Tokunaga, U. I. Chung and H. Kawaguchi: Transcriptional regulation of endochondral ossification by HIF-2 α during skeletal growth and osteoarthritis development. *Nat Med*, 16(6), 678-86 (2010)

190. B. L. Thoms and C. L. Murphy: Inhibition of hypoxia-inducible factor-targeting prolyl hydroxylase domain-containing protein 2 (PHD2) enhances matrix synthesis by human chondrocytes. *J Biol Chem*, 285(27), 20472-80 (2010)

191. S. Yang, J. Kim, J. H. Ryu, H. Oh, C. H. Chun, B. J. Kim, B. H. Min and J. S. Chun: Hypoxia-inducible factor-2 α is a catabolic regulator of osteoarthritic cartilage destruction. *Nat Med*, 16(6), 687-93 (2010)

192. P. M. van der Kraan, E. N. Blaney Davidson and W. B. van den Berg: Bone morphogenetic proteins and articular cartilage: To serve and protect or a wolf in sheep clothing's? *Osteoarthritis Cartilage*, 18(6), 735-41 (2010)

193. Z. Zhou, J. Xie, D. Lee, Y. Liu, J. Jung, L. Zhou, S. Xiong, L. Mei and W. C. Xiong: Neogenin regulation of BMP-induced canonical Smad signaling and endochondral bone formation. *Dev Cell*, 19(1), 90-102 (2010)

Key Words: TGF- β , osteoarthritis, cartilage, chondrocyte, TGF- β co-receptors, endoglin, betaglycan, CD109

Send correspondence to: Anie Philip, Division of Plastic Surgery, Montreal General Hospital, 1650 Cedar Avenue, Room C9-177, Montreal, QC, Canada H3G 1A4, Tel: 514-934 1934 ext 44535, Fax: 514-934 8289, E-mail: anie.philip@mcgill.ca

<http://www.bioscience.org/current/vol4S.htm>